To study alcoholic liver disease with unani medicine

A randomized single blind two arm clinical trial of polyherbal unani formulation in the treatment of alcoholic hepatitis in comparison of jigreena capsules - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/063162

Enrollment

Registered

2024-02-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K701- Alcoholic hepatitis

Interventions

Intervention1: Unani drugs: Each patient is treated with polyherbal unani formulation in form of capsules 3 gm per day containing 1. Rosa domestica (gule surkh), 2.Apium graveolens (tukhme karafs), 3.

Eligibility

Inclusion criteria

Inclusion criteria: 1.On going consumption of alcohol more than 40gm per day in female and more than 60gm per day in male. 2.Total serum bilirubin more than 1.2mg/dl 3.ALT more than 50 IU/dl.

Exclusion criteria

Exclusion criteria: 1.Pateint with Diabates and uncontrolled hypertension, uncontrolled drug addiction,latent tuberculosis. 2.patient with Auto immune disorders. 3.patient with active hepatitis-B and chronic hepatitis-C. 4.patient with increase creatinine level more than 2.5mg/dl.

Design outcomes

Primary

Measure	Time frame
To reduce ALT (Alanine transaminase) to normal value 50 IU/dl To reduce total serum bilirubin to normal 1.2mg/dlTimepoint: Serum ALT and serum bilirubin at every 15 days	—

Secondary

Measure	Time frame
To reduce hepatomegaly in alcoholic hepatitis patientsTimepoint: 30 days	—

Countries

India

Contacts

Public ContactDr Mohammed Junaid Ali

Govt Nizamia tibbi college and General Hospital

drsakhussaini@gmail.com9704888561

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026